Physician Fee Cuts Also a Possibility

Publication
Article
OncologyONCOLOGY Vol 15 No 10
Volume 15
Issue 10

As if the prospective Medicare cuts in payments for outpatient chemotherapy drugs were not troubling enough, there is another dark Medicare cloud. The American Medical Association (AMA) is predicting that Medicare may also cut physician

As if the prospective Medicare cuts in payments for outpatient chemotherapydrugs were not troubling enough, there is another dark Medicare cloud. TheAmerican Medical Association (AMA) is predicting that Medicare may also cutphysician fees across the board in 2002. A decision on that will not be madeuntil November, when the CMS presents final numbers for the Medicare EconomicIndex (MEI), an inflation adjustment, and the Sustainable Growth Rate (SGR),which describes how much under or over a preset target physicians’ bills toMedicare were in a given year. 

If physicians keep their billing below theincrease in the gross domestic product, then the MEI is increased, leading to ahigher fee "update." In the opposite scenario, the MEI is decreased.Based on preliminary forecasts, the AMA believes that physician fees could becut 2% to 3% in 2002. (That would be after increases of 5.4% and 4.5% in 2000and 2001.) The AMA is trying to get the CMS to make some administrative changesin the way the MEI and SGR are calculated—changes that perhaps would result ina zero change in 2002. But in a letter to medical specialty societies, RobertGilmore, MD, an AMA official, said, "I cannot overemphasize how difficultthis battle could be."

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content